As a consequence, inhibitors targeting its constituents, like PI3K inhibitors (e.g., alpelisib) and mTOR inhibitors (e.g., everolimus), have emerged as particularly potent against certain breast cancer variants [67]. The gene discussed is MTOR; the disease is breast carcinoma.